Enfuvirtide (fuzeon®): The first fusion inhibitor

International Journal of Clinical Practice

Volumn 57, Issue 10, 2003, Pages 890-897

  Williams, I G ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIRETROVIRUS AGENT; ENFUVIRTIDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; PEPTIDE FRAGMENT;

APPETITE DISORDER; BACTERIAL PNEUMONIA; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; EOSINOPHILIA; ERYTHEMA; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICENCE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PAIN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SKIN INDURATION; SKIN NODULE; TREATMENT FAILURE; VOMITING; COST BENEFIT ANALYSIS; ECONOMICS; PATIENT SATISFACTION; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

CLINICAL TRIALS, PHASE III; COST-BENEFIT ANALYSIS; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; PATIENT SATISFACTION; PATIENT SELECTION; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 0345874500     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Communicable Disease Surveillance Centre. AIDS and HIV infection in the United Kingdom: detailed analysis of the year HIV data 2002. CDR Weekly 2003; 13: 26-31.
2. CDSC. Sexually transmitted infections in the UK: new episodes seen at genitourinary medicine clinics, 1991-2001. Joint publication between PHLS (England, Wales & Northern Ireland), DHSS&PS (Northern Ireland) and the Scottish ISD(D)5 Collaborative Group.
3. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860.
4. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
5. British HIV Association Writing Committee, on behalf of the British HIV Association. BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy, 2003.
6. Phillips AN, Staszewski S, Weber R et al. Viral load changes in response to antiretroviral therapy according to baseline CD4 lymphocyte count and viral load. AIDS 2000; 14: S3. Abstract PL3.5.
7. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A et al. When to start HAART in chronically HIV-infected patients: a collection of pieces of evidence from the ICONA study. AIDS 2000; 14: S3. Abstract PL3.5.
8. Patterson D, Swindells S, Mohr J et al. How much adherence is enough? A prospective study of adherence to protease inhibitor therapy using MEMS caps. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, USA, 1999. Abstract 92.
9. Clevenbergh P, Durant J, Verbiest W et al. Phenotypic analysis of the Viradapt study: correlation with genotypic resistance and PI plasma levels. Antiviral Ther 2000; 5(suppl 3): 71-72.
10. Richman D, Bozzette S, Morton S et al. The prevalence of antiretroviral drug resistance in the US. 41st Interscience Conference on Antiviral Agents and Chemotherapy, Chicago, USA, 2001. Abstract LB-17.
11. Rousseau MN, Vergne L, Montes B et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J AIDS 2001; 26: 36-43.
12. Little SJ, Holte S, Routy JP et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394.
13. D'Souza MP. Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA 2000; 284: 215-222.
14. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998; 93: 681-684.
15. Kilby JM, Hopkins S, Venetta TM et al. Potent suppression of HIV-1 replication in humans by T-20 in combination with oral antiretroviral agents in an HIV-infected individual. Nature Med 1998; 4: 1302-1307.
16. Kilby JM, Eron J. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003; 348: 2228-2238.
17. Sista P, Melby T, Dhingra U et al. The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades. Antivir Ther 2001; 6(suppl 1): 8.
18. Sista P, Melby T, Greenberg S et al. Characterisation of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates. XI International HIV Drug Resistance Workshop, Seville, Spain, July 2002. Abstract 21.
19. Wei X, Decker JM, Liu H et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-1905.
20. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-2185.
21. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-2195.
22. Katlama C, Aresteh K Clotet B et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 2003. Abstract LB2.
23. Clotet B, Lassarin A, Cooper D et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen versus OB alone in patients with prior experience of resistance to each of the three classes of approved antiretrovirals (ARVs) in Europe and Australia. XIV International AIDS Conference, Barcelona, Spain, July 2002. Abstract LBOr19A.
24. Henry K, Lalezari J, O'Hearn M et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen versus OB alone in patients with prior experience of resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil (TORO 1) XIV International AIDS Conference, Barcelona, Spain, July 2002. Abstract LBOr19B.
25. Delfraissy JF, Montaner J, Eron J et al. Summary of pooled efficacy and safety analyses of enfuvirtide treatment for 24 weeks in TORO 1 and TORO 2 phase III trials in highly antiretroviral treatment experienced patients. 10th Conference on Retroviruses and Opportunistic Infections Boston, February 2003. Abstract 568.
26. Green J, Wintfeld N. Patient acceptance with self-injection of enfuvirtide (T-20) for HIV over 24 weeks of treatment. 6th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 2002. Abstract.
27. Roche. Data on file, 2003.
28. Cook J, Dasbach E, Coplan P et al. Modelling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels. AIDS Res Hum Retrovirus 1999; 15: 499-508.
29. Deeks SG. Duration and predictors of CD4+ cell T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002; 16: 201-207.
30. Weinstein MC, Goldie SJ, Losina E et al. Use of genotyping resistance testing to guide HIV therapy: clinical impact and cost effectiveness. Ann Intern Med 2001; 134: 440-450.
31. Montaner J, DeMasi R, Delehanty J et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France, July 2003. Abstract 116.
32. Miralles G, Lalezari J, Bellos N et al. T-1249 demonstrates potent antiviral activity over 10 day dosing in most patients who have failed a regimen containing ebfuvirtide: planned interim analysis of T-1249, a phase I/II study. 10th Conference on Retroviruses and Opportunistic infections, Boston, February 2003. Abstract 63.